Arcellx 향후 성장

Future 기준 점검 2/6

Arcellx (는) 각각 연간 59.1% 및 55.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 57.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -37.7% 로 예상됩니다.

핵심 정보

59.1%

이익 성장률

57.08%

EPS 성장률

Biotechs 이익 성장	23.9%
매출 성장률	55.3%
향후 자기자본이익률	-37.69%
애널리스트 커버리지	Good
마지막 업데이트	22 Dec 2025

최근 향후 성장 업데이트

Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results

Aug 10

Recent updates

Arcellx: Funded Into 2028 With Strong Clinical Data

Dec 17

Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results

Aug 10

Need To Know: Analysts Just Made A Substantial Cut To Their Arcellx, Inc. (NASDAQ:ACLX) Estimates

Mar 05

Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy

Jan 16

Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX)

Dec 20

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Oct 28

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Sep 10

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Sep 05

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Aug 10

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Jul 12

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Jun 01

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

May 14

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

May 12

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

이익 및 매출 성장 예측

NasdaqGS:ACLX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	264	-111	-97	14	13
12/31/2026	126	-194	-160	-118	17
12/31/2025	37	-226	-174	-170	18
9/30/2025	36	-218	-201	-198	N/A
6/30/2025	57	-188	-123	-118	N/A
3/31/2025	77	-162	-122	-115	N/A
12/31/2024	108	-107	-97	-83	N/A
9/30/2024	156	-40	4	21	N/A
6/30/2024	145	-54	-43	-20	N/A
3/31/2024	132	-51	-33	-6	N/A
12/31/2023	110	-71	186	208	N/A
9/30/2023	47	-130	104	122	N/A
6/30/2023	32	-183	105	115	N/A
3/31/2023	18	-190	113	115	N/A
12/31/2022	N/A	-189	-102	-99	N/A
9/30/2022	N/A	-170	-99	-93	N/A
6/30/2022	N/A	-95	-94	-89	N/A
3/31/2022	N/A	-80	-83	-77	N/A
12/31/2021	N/A	-65	-60	-54	N/A
9/30/2021	N/A	-53	-42	-40	N/A
12/31/2020	N/A	-32	-30	-29	N/A
12/31/2019	N/A	-18	-23	-19	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ACLX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ACLX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ACLX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ACLX 의 수익(연간 55.3%)이 US 시장(연간 10.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: ACLX 의 수익(연간 55.3%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ACLX는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/24 14:02
종가	2025/12/24 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Arcellx, Inc.는 26명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jack Allen	Baird
Jason Matthew Gerberry	BofA Global Research
John Newman	Canaccord Genuity

Arcellx 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus revenue estimates fall by 33%

Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 27%

Consensus EPS estimates fall by 11%

Recent updates

Arcellx: Funded Into 2028 With Strong Clinical Data

Arcellx, Inc. Announces New Positive Data from Its Pivotal Phase 2 iMMagine-1 Study of Anitocabtage Neautoleucel in Patients with Relapsed or Refractory Multiple Myeloma

Consensus revenue estimates fall by 33%

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcellx to Present New Data for its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Not Very Worried About Arcellx's (NASDAQ:ACLX) Cash Burn Rate

Chief Financial Officer notifies of intention to sell stock

Arcellx, Inc. Announces New Positive Data for Its Immagine-1 Study in Patients with Relapsed And/Or Refractory Multiple Myeloma

Consensus EPS estimates fall by 37%

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Arcellx, Inc., Annual General Meeting, May 28, 2025

We Think Arcellx (NASDAQ:ACLX) Can Easily Afford To Drive Business Growth

Arcellx Impressive Safety Data Leaves Doubts

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 27%

Need To Know: Analysts Just Made A Substantial Cut To Their Arcellx, Inc. (NASDAQ:ACLX) Estimates

Full year 2024 earnings: EPS and revenues miss analyst expectations

Chairman of the Board recently sold US$2.4m worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy

Chairman of the Board notifies of intention to sell stock

Insufficient new directors

Risks To Shareholder Returns Are Elevated At These Prices For Arcellx, Inc. (NASDAQ:ACLX)

Consensus EPS estimates fall by 11%

Chief Financial Officer notifies of intention to sell stock

Price target increased by 9.7% to US$105

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$89.67

Now 20% overvalued after recent price rise

Chief Financial Officer notifies of intention to sell stock

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$320k worth of stock

Consensus revenue estimates increase by 21%

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options and sold US$990k worth of stock

Now 21% overvalued after recent price rise

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Consensus revenue estimates increase by 14%

Chief Financial Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

New major risk - Revenue and earnings growth

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock